Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04900090
Other study ID # RC-P00106
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 25, 2021
Est. completion date August 31, 2021

Study information

Verified date March 2024
Source Lille Catholic University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of acute joint pain. As the disease progresses, the joint pain becomes chronic and associated with disabling and deformative manifestations called tophus. This disease is strongly associated with several comorbidities such as cardiovascular disease and chronic kidney failure. Gout is a very common disease, which is affecting 0.9% of the adult population in France and nearly 4% of the North-American population. Data from New Zealand show a particularly high prevalence of gout among Polynesians (minority populations in New Zealand and other islands of the South Pacific) that would be explained by genetic susceptibility and frequently interrelated metabolic diseases. Data on the Polynesian population in New Caledonia suggest prevalence figures close to 7% and prevalence in French Polynesia is assumed to be higher. International genomic studies of gout and hyperuricaemia have identified alleles associated with the occurrence of gout. The aim is to focus on families with several gouty members (numerous in French Polynesia, and geographically clustered) in order to enable the study of individuals with monogenic gout or with a low number of variants (= cases) determining in the occurrence of gout, as well as a non-gouty family member (= controls). Dual-energy CT scan (DECT) allows identification and quantification of UMS crystal deposits in the tissue. The volume of crystals correlates not only with the inflammatory activity of the disease but also with the comorbidities that complicate it. Dual-energy scanning has shown the presence of UMS crystals in some hyperuricemic individuals, which could help to identify those individuals most at risk of developing the disease as they already have the stigma of sub-clinical inflammatory activity.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date August 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria : Case group : - Gout patients - Polynesian origin - Aged 18 to 80 years - Agreeing to participate in the study - Having a 1st or 2nd degree relative who is also gouty and a 1st degree relative of the same generation and sex who is not gouty Control group : - Non-gouty individuals who are 1st degree relatives of a gouty patient of the same generation and sex - Aged 18 to 80 years - Agreeing to participate in the study Exclusion Criteria : - Pregnant women - Persons under guardianship, curatorship or other legal incapacity - Persons with a contraindication to Magnetic resonance imaging (MRI) examination - For non-gouty controls : current hyperuricemic treatment (Allopurinol, Febuxostat, Probenecid or Benzbromarone) - For gouty case : not participating in the TOPATA study (NCT04812886)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Epidemiological study
Clinical phenotypic assessment and neurosensory measures Biological, genetic and metabolomic evaluation Questionnaires (quality of life, gout, life habit, comorbidities) Morphological evaluation by Dual-energy CT scan

Locations

Country Name City State
French Polynesia Centre Hospitalier de Polynésie Française Papeete Ville De Pirae

Sponsors (5)

Lead Sponsor Collaborator
Lille Catholic University Ministry of Health, French Polynesia, University of Birmingham, University of San Diego, Variant Bio, Inc.

Country where clinical trial is conducted

French Polynesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multiple correlation between genetic variants and clinical presentation Genome-wide association study (GWAS) aims at identifying genetic variants (genotype) that associated with specific traits (phenotype).
The link between the genetic variants and the stage of the disease will be sought using a bivariate analysis: Chi-2 tests or Fisher's exact tests in case of small numbers will be implemented
4 months
Secondary Multiple correlation between disease stage, comorbidities, environmental and metabolomics data The link between variants will be stablish using a multivariate logistic regression model.- The comorbidities analysed are the following: initial uraemia, glomerular filtration rate (GFR), hypertension, chronic heart failure, diabetes, obesity (BMI > 30), obliterative arterial disease of the lower limbs, history of myocardial infarction, history of cerebrovascular accident
- The environmental data analysed were as follows: habitus data (alcohol consumption, soft drinks, physical activity)
4 months
Secondary Multiple correlation between severity of gout, its impact (pain, disease impact, and quality of life), presence of certain genetic variants, metabolomic changes and comorbidities The link between variants will be stablish using a multivariate logistic regression model. Quality of life will be assessed by the EuroQol questionnaire; perception of hyperuricemia-related illness by the Brief Hyperuricemia Perceptions Questionnaire (BIPQ); body and foot pain in the previous week by a VAS out of 100; activity limitations by the Health Assessment Questionnaire (HAQ-II); foot pain and disability by the Manchester Foot Pain and Disability Index (MFPDI). 4 months
Secondary Multiple correlation between genetic variants, comorbidities, environmental factors, presence of gout The link between variants will be stablish using a multivariate logistic regression model. Health status will be assessed by the following elements:
Perceived health status: good (modalities "very good" and "good") / bad ("average", "bad" and "very bad")
Total number of visits to a health professional in the last 12 monthsThe presence of gout will be determined using a calculation combining and weighting different responses to the questionnaires.
The diagnosis of gout is retained if the patient meets the 2015 ACR/EULAR criteria for diagnostic classification of gout.
4 months
See also
  Status Clinical Trial Phase
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Not yet recruiting NCT06187519 - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study N/A
Completed NCT03635957 - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Phase 4
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT03015948 - A Single Dose Study of SHR4640 in Healthy Male Volunteers Phase 1
Completed NCT02855437 - Novel Methods for Ascertainment of Gout Flares -A Pilot Study N/A
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Completed NCT00985127 - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT03291782 - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Phase 1
Recruiting NCT03388515 - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Enrolling by invitation NCT03336203 - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Phase 4
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT04047394 - A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers Phase 1
Not yet recruiting NCT05507723 - Tight Control of Gouty Arthritis Compared to Usual Care N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2